Target intelligence / Profile preview

Sigma non-opioid intracellular receptor 1 (SIGMAR1) (SIGMAR1)

Target
SIGMAR1
Molecular classification
Chaperone, Receptor, Transmembrane protein
01

Overview

Sigma non-opioid intracellular receptor 1 (SIGMAR1), also known as the Sigma-1 receptor or SR31747A-binding protein 1, is a unique ligand-regulated molecular chaperone primarily localized at the mitochondria-associated membrane (MAM) of the endoplasmic reticulum [6, 11]. It plays a critical role in cellular homeostasis by modulating calcium signaling through interactions with the inositol 1,4,5-trisphosphate receptor (IP3R) and regulating the folding of proteins [6, 12]. SIGMAR1 is highly expressed in the central nervous system and various peripheral tissues, and its dysfunction is implicated in a wide range of conditions, including neurodegenerative diseases like Alzheimer's and ALS, as well as psychiatric disorders and cancer [6, 12, 28]. The receptor is targeted by a diverse array of ligands, including the immunosuppressant and antiproliferative agent SR31747A, which binds with high affinity to inhibit tumor cell growth and modulate immune responses [1, 21, 22]. Therapeutic strategies targeting SIGMAR1 aim to leverage its neuroprotective and chaperone functions to treat neurological deficits or exploit its role in cell proliferation for oncology applications [11, 12, 19].

Other names
SR31747A-binding protein 1SRBP1SR-BP1OPRS1ALS16Sigma-1 receptorSigma-1R
02

Mechanism of action

Sigma-1 receptor antagonism (e.g., SR31747A), Sigma-1 receptor agonism (e.g., Fluvoxamine), Chaperone modulation, Ion channel regulation

03

Biological functions

Chaperone activityCalcium signaling regulationProtein foldingCell survivalNeuroprotectionLipid metabolism regulationIon channel modulation
04

Disease associations

CancerNeurodegenerative diseaseAlzheimer's diseaseParkinson's diseaseAmyotrophic lateral sclerosisSchizophreniaDepressionPainDrug addiction
05

Safety considerations

CNS side effectsPotential for off-target effects due to wide tissue distributionPotential for drug-drug interactions
06

Interacting drugs

SR31747A

8 more in the full profile.

07

Biomarkers

SIGMAR1 gene mutationsSigma-1 receptor density (PET imaging)

Beyond the preview

Go deeper on Sigma non-opioid intracellular receptor 1 (SIGMAR1) (SIGMAR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sigma non-opioid intracellular receptor 1 (SIGMAR1) (SIGMAR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call